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INTRODUCTION
Macrophages are the principal cell of innate im-
munity. They show active phagocytosis, produce
cytokines, present antigens to lymphocytes, and play
an important role in host defense against various mi-
croorganisms. In addition, macrophages actively me-
tabolize cholesterol and contribute to atherogenesis
by producing various biologically active molecules
(1). Macrophages in atheromatous plaques com-
monly accumulate numerous lipid droplets in their
cytoplasm. These unique macrophages are called
foamy transformed macrophages. Macrophages in
hyperlipidemic conditions actively internalize low-
density lipoprotein (LDL), with or without chemical
modification, via scavenger receptor-mediated endo-
cytosis or fluid-phase pinocytosis (2, 3). Internalized
modified or native LDL is hydrolyzed at acid lipase-
positive late endosomes, which results in the gen-
eration of free cholesterol in loco (4, 5). Free choles-
terol generated at late endosomes is transferred to
plasma membranes by Niemann-Pick disease type
C1/C2 protein (NPC1/2), and excess amounts of
transferred free cholesterol are further transported
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to the endoplasmic reticulum (ER), where acyl co-
enzyme A : cholesterol acyltransferase (ACAT) re-
sides. ACAT catalyzes the esterification of free cho-
lesterol, so that modified or native LDL-derived free
cholesterol is re-esterified at the ER, released into
the cytoplasm, and stored as lipid droplets. These
processes cause foamy transformation of the macro-
phages (4, 5).
During our morphological analysis of foamy trans-
formed macrophages, we discovered a unique, cho-
lesterol-induced, functional endosomal organelle :
ACAT1-positive late endosomes (ACAT1-LE). In
this review article, we describe our discovery of
ACAT1-LE and discuss the functional significance of
this unique cholesterol-induced organelle. In addi-
tion, we describe the clinical significance of ACAT1-
LE induction on the congenital endosomal storage
disease--Niemann Pick disease type C (NPC).
ACAT
The presence of a cholesterol-esterifying enzyme
in mammalian cells has been known since the 1960s.
Its enzymatic activity was usually detected in micro-
somal fractions, so ACAT is said to reside in the ER.
Chang et al. first cloned ACAT in 1993 (6), and ex-
tensive genetic investigations then produced the
cloned ACAT isozyme ACAT2 (after which the first
cloned ACAT was renamed ACAT1) (7). Most hu-
man somatic cells express ACAT1 ; in particular,
macrophages, adrenal cortex cells, and sebaceous
cells express a significant amount of ACAT1 (8). In
contrast, ACAT2 expression is limited to the apical
region of enterocytes, fetal hepatocytes, and well-
differentiated macrophages (9-11). Under physi-
ological conditions, ACAT functions in intracellular
cholesterol homeostasis in mammalian cells, espe-
cially in macrophages and steroid hormone-produc-
ing cells ; in addition, it regulates lipoprotein syn-
thesis in hepatocytes and enterocytes (5). Artificial
inhibition of ACAT enzymatic activity therefore
causes impaired lipoprotein synthesis as well as
ER stress-mediated apoptosis via free cholesterol-
induced cell toxicity (12).
In pathological situations, ACAT, by esterifying
cholesterol, serves a critical function as a protector
against free cholesterol-induced cell toxicity. The
presence of foamy transformed macrophages in
atherosclerotic plaques therefore indicates ACAT-de-
pendent macrophage protection against massive cho-
lesterol loading. Foamy transformed macrophages
in atheromatous plaques, i.e. macrophages with
massive cholesterol loading, continuously internalize
modified LDL via scavenger receptors. The key is-
sue for foamy transformed macrophages in athero-
matous plaques relates to sufficient ACAT1 expres-
sion (mature macrophages express both ACAT1
and ACAT2, and 90% of enzymatic activity derives
from ACAT1) (11). In fact, a high-fat diet fed to
atherogenic mice with ACAT1-null macrophages
led to a reduced number of foamy transformed
macrophages and consequently severe inflamma-
tion, which resulted in increased atheromatous
plaque formation (13). These data prompted us to
question how macrophages protect themselves from
cholesterol-induced cell toxicity. The answer to this
basic question is ACAT1-LE.
ACAT1 VESICLES AND ACAT1-LE
As noted above, ACAT is an ER-resident enzyme.
We confirmed the location of ACAT1 to be the tu-
bular ER membrane in normal human macrophages
(Figure 1A, intact M ) (14). Next, we tried to detect
the ACAT1 signal in macrophages under chole-
sterol-rich conditions. Treatment with a cholesterol
donor (acetylated LDL) caused the ACAT1 signal
in human macrophages to appear on small vesicles
approximately 100 nm in diameter (Figure 1A, cho-
lesterol-rich M ). The ER marker protein GRP78
also appeared on small vesicles after cholesterol
donor treatment (Figure 1B, cholesterol-rich M ).
Furthermore, both ACAT1 and GRP78 signals cor-
related with each other before and after foamy trans-
formation (Figure 1C), and the expression level of
ACAT1 did not change before and after cholesterol
donor treatment (data not shown). These data thus
indicate that cholesterol-rich, foamy transformed
macrophages produce ACAT1-positive vesicles via
ER fragmentation.
ACAT is a representative allosteric enzyme whose
enzymatic activity increases after cholesterol binds to
its allosteric site. We thus believed that formation of
ACAT1 vesicles would be related to allosteric regu-
lation. A series of investigations of the significance
of ACAT1 vesicle formation led to the discovery of
ACAT1-LE. As Figure 2 shows, separate ACAT1 sig-
nals and signals of the late endosomal marker protein
lysosomal-associated membrane protein 2 (LAMP2)
were detected in macrophages with no lipid accumu-
lation (Figure 2A, intact M ). In contrast, approxi-
mately 20% of the ACAT1 signal corresponded to the
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Figure 1 ACAT1 vesicle formation in cholesterol -rich macrophages
Human macrophages derived from peripheral blood monocytes with or without acetylated LDL treatment were subjected to immu-
noelectron microscopy (post-embedding method) and confocal laser scanning microscopy. (A) Immunoelectron microscopy after
using ACAT1-specific antibody. (B) Immunoelectron microscopy after using GRP78 (ER marker protein)-specific antibody. The inset
in A is an enlarged image. Arrows indicate specific signals. (C) Confocal laser scanning microscopy after using ACAT1-specific anti-
body (green) and GRP78-specific antibody (red). Yellow in the merged image indicates a colocalization signal. Details are provided in
the text. Adapted from references 9 and 14.
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LAMP2 signal in foamy transformed macrophages
(Figure 2A, cholesterol-rich M , Figure 2B). The
purified ACAT1-positive organelles from cholesterol-
rich macrophages contained LAMP2, but those from
intact macrophages did not (Figure 2C), and im-
munoelectron microscopy confirmed the presence
of the ACAT1 signal on beads containing phago-
somal membranes from only foamy transformed
macrophages (Figure 2D), not intact macrophages.
These data thus indicate that foamy transformed
macrophages form ACAT1-LE via ER fragmenta-
tion (14, 15).
A
B
C D
Figure 2 ACAT1-LE in intact and cholesterol -rich macrophages
(A, B) Human macrophages derived from blood-borne monocytes with or without aggregated LDL treatment were subjected to im-
munofluorescence staining and quantitative colocalization analysis. The green signal indicates ACAT1, the magenta signal indicates
LAMP2, and the white signal indicates colocalization. DIC indicates differential interference contrast microscopy. (C) Macrophages
with or without aggregated LDL treatment were homogenized and subjected to immunoadsorption with beads conjugated to ACAT1-
specific antibody. Immunoadsorbed ACAT1-positive particles were analyzed by means of immunoblotting. Sup., supernatant. (D) Macro-
phages with or without methyl -β -cyclodextrin-cholesterol complex (mβCD-cho) treatment (cholesterol donor) were incubated with
fluorescent beads to investigate phagocytosis. Macrophages after phagocytosis were homogenized and subjected to ultracentrifugation
to collect beads containing phagosomes, and the phagosomal fraction was further subjected to immunoelectron microscopy (pre-
embedding technique). Arrows indicate ACAT1-positive colloidal gold signals. Details are provided in the text. Adapted from refer-
ences 14 and 15.
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ACAT1-LE AND CHOLESTEROL METABO-
LISM
As described above, the late endosome is an or-
ganelle that contains free cholesterol derived from
internalized LDL, and ACAT1 is an enzyme that es-
terifies free cholesterol. ACAT1-LE would therefore
be an organelle that would re-esterify LDL-derived
free cholesterol in loco . To demonstrate efficient
cholesterol esterification at endosomes, we investi-
gated cholesterol esterification kinetics in macro-
phages with ACAT1-LE. Figure 3A illustrates that
intact macrophages required at least 2 hours to re-
esterify LDL-derived free cholesterol because of
the complex intracellular cholesterol trafficking
system described here, in the Introduction. In con-
trast, foamy transformed macrophages with ACAT1-
LE esterified a significant amount of LDL-derived
cholesterol within 30 minutes. This finding suggests
efficient cholesterol esterification in ACAT1-LE-
positive macrophages. To demonstrate directly that
ACAT1-LE is the site of cholesterol esterification,
we performed an experiment in which cholesterol
egress was inhibited. U18666A is an amphiphilic
amino-steroid that blocks free cholesterol egress
from late endosomes by interfering with the choles-
terol trafficking protein NPC1 (5). Macrophages
treated with U18666A showed negligible cholesterol
esterification because no cholesterol reached the
ER, where ACAT1 resides. In contrast, foamy trans-
formed ACAT1-LE-positive macrophages esterified
a significant amount of free cholesterol even in the
presence of U18666A (Figure 3B). These data are
direct evidence of cholesterol esterification at the
ACAT1-LE, i.e. this unique organelle effectively es-
terified LDL-derived free cholesterol just after LDL
hydrolysis at late endosomes. This finding stimu-
lated us to pursue the therapeutic application of
ACAT1-LE to NPC.
NPC AND ACAT1-LE INDUCTION
Niemann-Pick disease is a congenital lysosomal
storage disease characterized by massive sphingo-
myelin accumulation. This disease was traditionally
classified as type A to type E according to its clinical
manifestations, but molecular analysis of the disease
led to reclassification of types according to two cri-
teria : Niemann-Pick disease type A, with an acid
sphingomyelinase deficiency, and NPC, with an
NPC1 protein deficiency (16). Deletion of the NPC1
protein causes free cholesterol accumulation in late
endosomes, which results in inhibition of acid sphin-
gomyelinase. As a result, NPC accumulates free
cholesterol as well as sphingomyelin, with conse-
quent cell injury. One possible therapeutic strategy
for NPC is using methyl-β -cyclodextrin (mβCD),
which is a cyclic oligosaccharide, to incorporate
hydrophobic molecules such as cholesterol. mβCD
is internalized via pinocytosis, remains at late en-
dosomes, and removes accumulated free cholesterol
from late endosomes and plasma membranes of
cells with the NPC phenotype (npc-/-) (17). Admini-
stration of mβCD to npc-/- mice ameliorated tissue
injury and prolonged survival, and this beneficial ef-
fect was also observed in patients with NPC (18, 19).
A
B
Figure 3 Functional analysis of ACAT1-LE
(A) Human macrophages derived from blood-borne monocytes
with or without mβCD-cho (cholesterol donor) treatment were
incubated with [3H]cholesterol - labeled acetylated LDL. Macro-
phages after incubation with radiolabeled acetylated LDL were
subjected to the [3H]cholesteryl ester formation assay. (B) Hu-
man macrophages with or without treatment with mβCD-cho
and the amphiphilic amino-steroid U18666A were incubated with
[3H]cholesterol - labeled acetylated LDL. They were then sub-
jected to the [3H]cholesteryl ester formation assay. Details are
provided in the text. Adapted from references 14 and 15.
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In contrast to the approach of removing choles-
terol by using mβCD, we believed that inducing
ACAT1-LE in npc-/- macrophages would also effec-
tively reduce the intracellular cholesterol level by
means of cholesterol esterification. Indeed, treat-
ment with mβCD-cholesterol complex (mβCD-cho),
a cholesterol donor, effectively produced ACAT1-
LE-positive npc-/- macrophages. These ACAT1-LE-
positive npc-/- macrophages showed significant
cholesterol esterification and effective reduction of
the intracellular cholesterol level (Figure 4A). In
addition, administration of mβCD-cho to npc-/- neo-
nate mice effectively extended their survival to the
same level as did conventional cholesterol remover
treatment (Figure 4B) (20). These data thus show
that induction of ACAT1-LE in patients with NPC
may be an alternative therapeutic approach (Figure
5).
A B
Figure 4 Therapeutic application of ACAT1-LE to NPC
(A) Bone marrow-derived macrophages with the NPC phenotype (npc1-/-) with or without mβCD-cho treatment were then incubated
with [3H]cholesterol - labeled acetylated LDL, after which they were subjected to the [3H]cholesteryl ester formation assay. (B) At 7 days
after birth, npc1-/- neonates were treated with mβCD-cho (cholesterol donor) or mβCD (cholesterol remover). Survival of npc1-/-
mice after treatment was determined. Details are provided in the text. Adapted from reference 20.
Figure 5 Schematic explanation of ACAT1-LE formation in NPC
In NPC, deficiency of the NPC1 protein causes massive accumulation of exogenous LDL-derived free cholesterol in late endosomes/
lysosomes (LE/LS) in macrophages. This process results in significant cell injury and cell death. In contrast, pretreatment of macro-
phages with mβCD-cho induces ACAT1-LE and esterification of free cholesterol in loco , which results in reduced cell injury and greater
cell survival. Adapted from reference 20.
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CLOSING REMARKS
The question of whether intracellular ACAT1 lo-
calization would change under cholesterol-rich con-
ditions (i.e. substrate-rich conditions for ACAT1)
in human macrophages led us to discover ACAT1-
LE and an alternative treatment strategy for NPC.
Although in this review we did not mention the
ACAT1-LE degradative pathway, ACAT1-LE has
an impaired degradative pathway that depends on
ACAT enzymatic activity. The late endosome is not
only the principal organelle in the intracellular degra-
dative pathway but is also the sorting compartment
for protein synthesis. Therefore, ACAT1-LE-positive
foamy transformed macrophages may manifest im-
paired protein sorting, which in hyperlipidemic con-
ditions would result in disturbed protein synthesis
such as cytokine production. Further research must
clarify the details of ACAT1-LE function and its
medical significance.
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